THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES

二甲双胍是目前治疗2型糖尿病使用最广泛的降糖药物之一，有效地用于治疗2型糖尿病。除了抗糖尿病作用外，二甲双胍似乎还具有重要的附加特性，这些特性可能在药理上与人类的长期健康和福利有关。因此，在IRP，NIA内正在对啮齿动物进行翻译研究，以评估二甲双胍在给予正常和混合饮食--包括高脂肪--的啮齿动物中对一些与健康相关的药效学措施的潜在有益作用。药代动力学--具体而言，解释药效学数据和协助跨物种翻译研究需要二甲双胍的血液和组织水平--重点是人类。该任务顺序支持对IRP NIA研究中产生的血浆和组织样本中二甲双胍药物水平的定量分析。

Metformin is one of the most widely used glucose-lowering drugs that is effectively used for the current treatment of type 2 diabetes mellitus. In addition to anti-diabetic action, metformin appears to possess important additional properties that may be pharmacologically relevant to long-term human health and welfare. Translational studies are therefore being undertaken in rodents within IRP, NIA, to evaluate potentially beneficial actions of metformin on a number of pharmacodynamics measures of relevance to health in rodents administered normal and assorted diets – including high fat. Pharmacokinetics – specifically, metformin blood and tissue levels are required to interpret pharmacodynamic data and aid in translation studies across species – with an emphasis on humans. This Task Order supports the quantitative analysis of metformin drug levels in plasma and tissue samples generated in IRP NIA research studies.